{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:26:44Z","timestamp":1792099604316,"version":"4.4.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T00:00:00Z","timestamp":1677110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The increased risk of cardiovascular events in patients prescribed macrolides has been subject to debate for decades.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Medline, EMBASE databases and <jats:ext-link>ClinicalTrials.gov<\/jats:ext-link> were searched from inception until August 31, 2022 for studies investigating the link between macrolides and cardiovascular risk. A meta-analysis was performed using a random-effects model.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 80 studies involving 39,374,874 patients were included. No association was found between macrolides and all-cause death. However, compared with the non-macrolide group, macrolides were associated with a significantly increased risk of ventricular arrhythmia or sudden cardiac death (VA or SCD) (azithromycin, relative ratio [RR]: 1.53; 95% confidence interval [CI]: 1.19 to 1.97; clarithromycin, RR: 1.52; 95% CI: 1.07 to 2.16). Besides, administration of macrolides was associated with a higher risk of cardiovascular disease (CVD) death (azithromycin, RR: 1.63; 95% CI: 1.17 to 2.27) and a slightly increased risk of myocardial infarction (MI) (azithromycin, RR: 1.08; 95% CI: 1.02 to 1.15). Interestingly, no association was observed between roxithromycin and adverse cardiac outcomes. Increased risk of VA or SCD was observed for recent or current use of macrolides, MI for former use, and CVD death for current use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Administration of macrolide antibiotics and timing of macrolide use are associated with increased risk for SCD or VTA and cardiovascular death, but not all-cause death.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2023.1117254","type":"journal-article","created":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T13:21:46Z","timestamp":1677158506000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["Administration of macrolide antibiotics increases cardiovascular risk"],"prefix":"10.3389","volume":"10","author":[{"given":"Yang","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Tao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ping","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Jun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Cheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu-Miao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Juan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Jiu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1164\/rccm.201402-0385CI","article-title":"Macrolide antibiotics and the risk of cardiac arrhythmias.","volume":"189","author":"Albert","year":"2014","journal-title":"Am J Respir Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: population based study.","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ."},{"key":"B3","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2015.09.029","article-title":"The role of macrolide antibiotics in increasing cardiovascular risk.","volume":"66","author":"Cheng","year":"2015","journal-title":"J Am Coll Cardiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e00438","DOI":"10.1128\/AAC.00438-18","article-title":"Systematic review, meta-analysis, and network meta-analysis of the cardiovascular safety of macrolides.","volume":"62","author":"Gorelik","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1503\/cmaj.150901","article-title":"Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.","volume":"188","author":"Trac","year":"2016","journal-title":"CMAJ."},{"key":"B6","year":"2018","journal-title":"FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the Risk of Potentially Fatal Heart Rhythms."},{"key":"B7","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.","volume":"397","year":"2021","journal-title":"Lancet."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ."},{"key":"B9","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ."},{"key":"B10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40264-017-0533-2","article-title":"Managing cardiovascular risk of macrolides: systematic review and meta-analysis.","volume":"40","author":"Wong","year":"2017","journal-title":"Drug Saf."},{"key":"B11","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/cid\/cis414","article-title":"Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.","volume":"55","author":"Asadi","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ejim.2015.09.009","article-title":"Association of macrolides with overall mortality and cardiac death among patients with various infections: a meta-analysis.","volume":"28","author":"Li","year":"2016","journal-title":"Eur J Intern Med."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226637","article-title":"Clarithromycin use and the risk of mortality and cardiovascular events: a systematic review and meta-analysis.","volume":"14","author":"You","year":"2019","journal-title":"PLoS One."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1235","article-title":"Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies.","volume":"346","author":"Schembri","year":"2013","journal-title":"BMJ."},{"key":"B15","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1001\/jama.2013.282426","article-title":"Calcium-channel blocker-clarithromycin drug interactions and acute kidney injury.","volume":"310","author":"Gandhi","year":"2013","journal-title":"JAMA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega","year":"2009","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1476-5381.2010.00881.x","article-title":"Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.","volume":"161","author":"Zahno","year":"2010","journal-title":"Br J Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ahj.2004.01.016","article-title":"Effects of a brief course of azithromycin on soluble cell adhesion molecules and markers of inflammation in survivors of an acute coronary syndrome: a double-blind, randomized, placebo-controlled study.","volume":"148","author":"Hillis","year":"2004","journal-title":"Am Heart J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on expert consensus decision pathways.","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J Am Coll Cardiol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/1755-5922.12054","article-title":"Antibiotic-induced cardiac arrhythmias.","volume":"32","author":"Abo-Salem","year":"2014","journal-title":"Cardiovasc Ther."},{"key":"B21","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome.","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacol Rev."},{"key":"B22","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1124\/jpet.302.1.320","article-title":"Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics.","volume":"302","author":"Volberg","year":"2002","journal-title":"J Pharmacol Exp Ther."},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","volume":"56","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents."},{"key":"B24","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41591-020-0888-2","article-title":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.","volume":"26","author":"Chorin","year":"2020","journal-title":"Nat Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1016\/j.mayocp.2020.03.024","article-title":"Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19).","volume":"95","author":"Giudicessi","year":"2020","journal-title":"Mayo Clin Proc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1183\/09031936.00054108","article-title":"Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.","volume":"33","author":"Restrepo","year":"2009","journal-title":"Eur Respir J."},{"key":"B27","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1183\/09031936.00136712","article-title":"Long-term macrolide treatment for chronic respiratory disease.","volume":"42","author":"Spagnolo","year":"2013","journal-title":"Eur Respir J."},{"key":"B28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11908-007-0016-1","article-title":"Macrolide immunomodulation of chronic respiratory diseases.","volume":"9","author":"Healy","year":"2007","journal-title":"Curr Infect Dis Rep."},{"key":"B29","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death.","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.115.003560","article-title":"Azithromycin causes a novel proarrhythmic syndrome.","volume":"10","author":"Yang","year":"2017","journal-title":"Circ Arrhythm Electrophysiol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1370\/afm.1601","article-title":"Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death.","volume":"12","author":"Rao","year":"2014","journal-title":"Ann Fam Med."},{"key":"B32","doi-asserted-by":"crossref","first-page":"E791","DOI":"10.1503\/cmaj.200879","article-title":"Death, discharge and arrhythmias among patients with COVID-19 and cardiac injury.","volume":"192","author":"Si","year":"2020","journal-title":"CMAJ."},{"key":"B33","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.hrthm.2020.06.016","article-title":"COVID-19 and cardiac arrhythmias.","volume":"17","author":"Bhatla","year":"2020","journal-title":"Heart Rhythm."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061867","article-title":"Pharmacovigilance study of hydroxychloroquine cardiac safety profile: potential implication in COVID-19 mitigation.","volume":"9","author":"Singh","year":"2020","journal-title":"J Clin Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1124\/jpet.109.155838","article-title":"Azithromycin and clarithromycin inhibit lipopolysaccharide-induced murine pulmonary neutrophilia mainly through effects on macrophage-derived granulocyte-macrophage colony-stimulating factor and interleukin-1beta.","volume":"331","author":"Bosnar","year":"2009","journal-title":"J Pharmacol Exp Ther."},{"key":"B36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1128\/AAC.46.2.409-412.2002","article-title":"Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection model.","volume":"46","author":"Kutlin","year":"2002","journal-title":"Antimicrob Agents Chemother."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1117254\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,23]],"date-time":"2023-02-23T13:21:55Z","timestamp":1677158515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1117254\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,23]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2023.1117254"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1117254","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,23]]},"article-number":"1117254"}}